Update shared on13 Sep 2025
Fair value Decreased 2.15%ICON’s consensus price target has been revised down from $220.40 to $215.67 as analysts express caution over persistent revenue and booking growth risks, customer cancellations, and macro uncertainty, which offset recent partnership gains and stable sector demand.
Analyst Commentary
- Bearish analysts highlighted persistent revenue and EBITDA growth risks in 2026 tied to lower-than-normal book-to-bills (BtBs) and customer cancellations, with consensus estimates seen as too optimistic.
- Channel checks and data point to ongoing wallet share losses, sustained booking and cancellation headwinds, and the potential for further guidance cuts, undermining momentum gained from recent partnership wins.
- Macro and policy-related uncertainties, particularly from administration changes, are expected to limit near-term visibility and continue as sector-wide overhangs, especially for the first half of FY25.
- Bullish analysts cited strong gross bookings, above-expectation BtB improvements in Q2, stable pharma trends, biotech recovery, higher cardio-metabolic demand, and Icon’s share gains as reasons for optimism regarding demand.
- Some bullish arguments also point to a favorable risk/reward scenario and historically attractive valuations for CROs, even with reduced forecasts, supporting potential upside despite near-term volatility.
What's in the News
- Dr. Steve Cutler will retire as ICON's CEO effective October 1, 2025, with current COO Barry Balfe appointed as successor; Cutler will continue on the Board as a non-executive director to support the leadership transition (Key Developments).
- A major next-generation COVID vaccine trial managed by ICON was halted mid-enrollment following a stop work order from BARDA; revenue for H2 2025 will be impacted, but full-year guidance remains unchanged (Key Developments).
- ICON increased its share repurchase authorization by $500 million to $1.25 billion and completed a $250 million repurchase (2.15% of shares) in Q2 2025; the company remains active in evaluating acquisition opportunities and continued internal investments, especially in technology platforms and lab services (Key Developments).
- ICON raised its full-year 2025 revenue guidance by approximately 1% at the midpoint, now expecting between $7.85 billion and $8.15 billion (Key Developments).
- NIH's decision to suspend cancellation of additional research grants, following legal challenges, provided a modest recovery for ICON shares, although the stock remained down amid sector movements (NY Times/Periodicals).
Valuation Changes
Summary of Valuation Changes for ICON
- The Consensus Analyst Price Target has fallen slightly from $220.40 to $215.67.
- The Future P/E for ICON remained effectively unchanged, moving only marginally from 17.57x to 17.25x.
- The Consensus Revenue Growth forecasts for ICON remained effectively unchanged, at 2.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.